SCHEMBL654468

SCHEMBL654468

O=C1[N]N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14932121 0.58
SCHEMBL3092227 0.47
SCHEMBL30107638 0.47
SCHEMBL29525411 0.45 KDM4E (0.40)
SCHEMBL29525891 0.45 KDM4E (0.40)
Water SCHEMBL29123856 0.41 KDM4E (0.46)
Hydrogen Sulfide SCHEMBL23805182 0.33
SCHEMBL2732127 0.33
SCHEMBL5137160 0.33
SCHEMBL5471826 0.33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658081-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA Bioscience nv (BE) 2006-05-24 EP claimed
WO-2005021003-A2 IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES 4 AZA BIOSCIENCE NV (BE) 2005-03-10 WO claimed
US-20040077859-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2004-04-22 US claimed
US-20240231224-A9 HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF LAM RESEARCH CORPORATION 2024-07-11 US disclosed
WO-2024137876-A2 SURFACE MODIFICATION OF METAL CATALYSTS WITH HYDROPHOBIC LIGANDS OR IONOMERS TWELVE BENEFIT CORPORATION (US) 2024-06-27 WO disclosed
US-20240200208-A1 CO2 PURIFICATION AND REDUCTION SYSTEMS SUMITOMO MITSUI BANKING CORPORATION 2024-06-20 US disclosed
US-20240192590-A1 APPARATUS AND PROCESS FOR EUV DRY RESIST SENSITIZATION BY GAS PHASE INFUSION OF A SENSITIZER LAM RESEARCH CORPORATION 2024-06-13 US disclosed
WO-2024123514-A1 CO2 PURIFICATION AND REDUCTION SYSTEMS TWELVE BENEFIT CORPORATION (US) 2024-06-13 WO disclosed
WO-2024108304-A1 DITHIOL CHELATORS FOR METAL CONJUGATION TO ANTIBODIES STANDARD BIOTOOLS CANADA INC. (CA) 2024-05-30 WO disclosed
US-20240134274-A1 HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF LAM RES CORP (US) 2024-04-25 US disclosed
WO-2024081174-A1 OXYMETHYLENE COPOLYMERS FOR TRANSIENT SURFACE PROTECTION DURING CHEMICAL VAPOR DEPOSITION LAM RESEARCH CORPORATION (US) 2024-04-18 WO disclosed
US-20020028823-A1 THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME CELL THERAPEUTICS, INC. 2002-03-07 US disclosed
EP-1171442-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS CELL THERAPEUTICS, INC. (US) 2002-01-16 EP disclosed
WO-2000061583-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 2000-10-19 WO disclosed
US-5824677-A SUBSTITUTED WITH HETEROCYCLIC RING, ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE CELL THERAPEUTICS, INC. (US) 1998-10-20 US disclosed
US-5777117-A ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE, CYTOTOXIC AGENTS; MICROBIOCIDES, FUNGICIDES CELL THERAPEUTICS, INC. (US) 1998-07-07 US disclosed
US-5750575-A ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANTS; CYTOTOXIC AGENTS; MICROBIOCIDES; FUNGICIDES CELL THERAPEUTICS, INC. (US) 1998-05-12 US disclosed
US-5670507-A Method for reversing multiple drug resistant phenotype CELL THERAPEUTICS, INC. (US) 1997-09-23 US disclosed
US-5641783-A ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS CELL THERAPEUTICS, INC. (US) 1997-06-24 US disclosed
WO-1995013808-A1 METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION CELL THERAPEUTICS, INC. (US) 1995-05-26 WO disclosed